Cardinal Health’s Giacomin re-elected as HDA board chairman
ARLINGTON, Va. — The Healthcare Distribution Alliance will be retaining Cardinal Health pharmaceutical segment CEO as its board chairman. The organization on Tuesday announced Jon Giacomin’s re-election to the position he has served in since 2016. Also continuing in his position on the board is vice chairman Henry Dale Smith, Jr., who is chairman and CEO of Smith Holding Co.
“HDA is pleased to welcome back Jon and Dale —their steady leadership will help shape the Alliance’s efforts to promote the critical role of pharmaceutical distributors, whose expertise ensures the safety and efficiency of the supply chain every day,” HDA president and CEO John Gray said.
In addition to Giacomin’s and Smith’s re-election, HDA appointed three new members — HPC Rx CEO Fred Battah, CuraScript SD president Earl English and Principal Dynamics CEO and Quality Care Products CEO Michael Holmes.
Teva relaunches Depo-Provera generic
JERUSALEM — Teva is reintroducing its generic of Depo-Provera (medroxyprogesterone acetate injectable suspension, 150 mg/mL) contraceptive injection. The drug is indicated to prevent pregnancy.
“This reintroduction brings an additional product to a market that was previously lacking in options,” Teva EVP and president of global generics research and development Dr. Hafrun Fridriksdottir said. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”
The reintroduction adds to Teva’s generic injectable business, which the company has been focused on growing. The drug had U.S. sales of approximately $211 million, according to QuintilesIMS data for the 12 months ended July 2017.
Lupin’s generic Clobex lotion gets FDA approval
SILVER SPRING, Md. — Lupin is adding to its topical generics portfolio. The Food and Drug Administration has approved Lupin’s generic of Galderma Laboratories’ Clobex (clobetasol propionate, 0.05%) lotion, the company announced Tuesday.
The product is indicated to relieve various corticosteroid-responsive dermatoses in patients ages 18 years and older. For the 12 months ended June 2017, the drug had U.S. sales of $14.3 million, according to QuinitlesIMS data.